MX2024009974A - Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc. - Google Patents
Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc.Info
- Publication number
- MX2024009974A MX2024009974A MX2024009974A MX2024009974A MX2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A
- Authority
- MX
- Mexico
- Prior art keywords
- cns
- treatment
- related disorders
- neuroactive steroids
- additional antidepressant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310581P | 2022-02-16 | 2022-02-16 | |
| US202263337828P | 2022-05-03 | 2022-05-03 | |
| US202363482200P | 2023-01-30 | 2023-01-30 | |
| PCT/US2023/013098 WO2023158668A1 (en) | 2022-02-16 | 2023-02-15 | Neuroactive steroids for treatment of cns-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009974A true MX2024009974A (es) | 2024-09-30 |
Family
ID=85569830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009974A MX2024009974A (es) | 2022-02-16 | 2023-02-15 | Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250295674A1 (https=) |
| EP (1) | EP4479032A1 (https=) |
| JP (1) | JP2025508406A (https=) |
| KR (1) | KR20240148425A (https=) |
| CN (1) | CN119072304A (https=) |
| AU (1) | AU2023220976A1 (https=) |
| CA (1) | CA3252357A1 (https=) |
| IL (1) | IL315023A (https=) |
| MX (1) | MX2024009974A (https=) |
| TW (1) | TW202341995A (https=) |
| WO (1) | WO2023158668A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| AU2022266680A1 (en) * | 2021-04-29 | 2023-11-02 | Sage Therapeutics, LLC | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| CN117442618B (zh) * | 2023-10-23 | 2025-11-14 | 国科大杭州高等研究院 | 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2023
- 2023-02-15 EP EP23710570.5A patent/EP4479032A1/en active Pending
- 2023-02-15 KR KR1020247030934A patent/KR20240148425A/ko active Pending
- 2023-02-15 JP JP2024548386A patent/JP2025508406A/ja active Pending
- 2023-02-15 US US18/839,147 patent/US20250295674A1/en active Pending
- 2023-02-15 TW TW112105363A patent/TW202341995A/zh unknown
- 2023-02-15 WO PCT/US2023/013098 patent/WO2023158668A1/en not_active Ceased
- 2023-02-15 MX MX2024009974A patent/MX2024009974A/es unknown
- 2023-02-15 IL IL315023A patent/IL315023A/en unknown
- 2023-02-15 AU AU2023220976A patent/AU2023220976A1/en active Pending
- 2023-02-15 CN CN202380033285.6A patent/CN119072304A/zh active Pending
- 2023-02-15 CA CA3252357A patent/CA3252357A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250295674A1 (en) | 2025-09-25 |
| JP2025508406A (ja) | 2025-03-26 |
| IL315023A (en) | 2024-10-01 |
| CN119072304A (zh) | 2024-12-03 |
| KR20240148425A (ko) | 2024-10-11 |
| EP4479032A1 (en) | 2024-12-25 |
| AU2023220976A1 (en) | 2024-09-05 |
| WO2023158668A1 (en) | 2023-08-24 |
| CA3252357A1 (en) | 2023-08-24 |
| TW202341995A (zh) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009974A (es) | Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc. | |
| MX2023009610A (es) | Esteroides neuroactivos, y su metodo de uso. | |
| MX2023007027A (es) | Derivado de cannabinoide como compuesto farmaceuticamente activo y metodo de preparacion del mismo. | |
| MX2022000733A (es) | Derivados cannabinoides como compuestos farmaceuticamente activos y metodos de preparacion de los mismos. | |
| MX2022013698A (es) | Dispositivos de administracion transdermica de farmacos que contienen psilocibina, dietilamida de acido lisergico o microprotuberancias recubiertas con 3,4-metilendioximetanfetamina. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| NZ751690A (en) | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2023013247A (es) | Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje. | |
| ECSP22086300A (es) | Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas | |
| MX2023012727A (es) | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2023000763A (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. | |
| CO2023016136A2 (es) | Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1) | |
| MX2023009600A (es) | Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias. | |
| MX2020012925A (es) | Producto inmunogeno que comprende il-4 y/o il-13 para el tratamiento de enfermedades asociadas con la expresion o actividad aberrante de il-4 y/o il 13. | |
| BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
| MX2021011263A (es) | Uso de moduladores del receptor gabaa para el tratamiento del dolor. | |
| MX2022000356A (es) | Compuesto para tratamiento de combinacion. | |
| BRPI0617382A2 (pt) | Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento | |
| AR047716A1 (es) | Combinaciones de analepticos y antidepresivos | |
| MX2022000082A (es) | Composiciones terapeuticas y metodos para tratar canceres. |